The survey was carried out on healthcare workers at the largest hospital in Israel, which on December 19 launched a mass vaccination campaign regarded as the world’s fastest.
Meanwhile, Moscow announced Saturday it had registered its third vaccine against the coronavirus and promised to introduce the jab to the Russian population by March.
Russia was the first country to register a vaccine against COVID-19 in August ahead of clinical trials, and the Sputnik V jab has been authorized in more than two dozen countries around the world.
“Today we note that a third vaccine, CoviVac, has been registered,” Prime Minister Mikhail Mishustin said at a government meeting broadcast on state television.
“And already in mid-March, the first 120,000 doses will be distributed within the civilian circulation,” he told the cabinet.
Israeli studies have found the vaccine developed by US pharma giant Pfizer and its German partner BioNTech to be 95 percent effective one week after a second jab, while the Lancet report focused on more than 9,000 medical staff at Sheba hospital near Tel Aviv.
Some 7,000 of them received the first dose and the rest were not inoculated.
From the group, 170 were diagnosed with Covid-19 after tests carried out only on those showing symptoms or who had been in contact with coronavirus carriers.
Fifty-two percent of them were found to have not been vaccinated.
Comparing the two groups, the Sheba study calculated that the vaccine was 47 percent effective between one and 14 days after inoculation, rising to 85 percent after 15 to 28 days.
“What we see is a really high effectiveness already right after two weeks, between two weeks to four weeks after vaccine, already high effectiveness of 85 percent reduction of symptomatic infection,” Gili Regev-Yochay, co-author of the study, told a small group of journalists.
He said that despite the vaccine being “amazingly effective”, scientists are still studying whether fully vaccinated people can transmit the virus to others.
“That is the big, big, question. We are working on it. This is not on this paper and I hope we will have some good news soon,” said Regev-Yochay.
Israel has delivered a shot of the Pfizer/BioNTech vaccine to 4.23 million residents, or 47 percent of its nine million population, 2.85 million of whom have received the recommended full course of two jabs, latest health ministry figures show.
Separately on Friday, Pfizer and BioNTech said their vaccine can stand warmer temperatures than initially thought, potentially simplifying the jab’s complex cold-chain logistics.
The companies said they have asked the US Food and Drug Administration to allow for the vaccine to be stored for up to two weeks at minus 25 to minus 15 degrees Celsius (minus 13 to five degrees Fahrenheit) — temperatures commonly found in pharmaceutical freezers and refrigerators.
Under the existing guidelines, the Pfizer/BioNTech jab needs to be stored at a frigid minus 80 to minus 60 C until five days before use, a delicate process that requires special ultra-cold containers for shipping and dry ice for storage.
COMMENT DISCLAIMER: Reader comments posted on this Web site are not in any way endorsed by Manila Standard. Comments are views by manilastandard.net readers who exercise their right to free expression and they do not necessarily represent or reflect the position or viewpoint of manilastandard.net. While reserving this publication’s right to delete comments that are deemed offensive, indecent or inconsistent with Manila Standard editorial standards, Manila Standard may not be held liable for any false information posted by readers in this comments section.